ArchiveJanuary 2013

Vitamin D receptor in the brain of MSers

#MSBlog: What does vD do in the brains of MSers? Is it a chicken or egg debate? Smolders et al. Expression of Vitamin D Receptor and Metabolizing Enzymes in Multiple Sclerosis-Affected Brain Tissue. J Neuropathol Exp Neurol. 2013;72(2):91-105. BACKGROUND: Vitamin D deficiency has been implicated as a risk factor for MS, but how vitamin D metabolism affects MS pathophysiology is not understood...

CCSVI monthly January

Epub: Carraro et al. Optic Nerve and its Arterial-Venous Vascularization: An Ultrasonologic Study in Multiple SclerosisPatients and Healthy Controls.J Neuroimaging. 2012 Dec. doi: 10.1111/j.1552-6569.2012.00758.x. BACKGROUND: Recent studies suggest that alterations in the cerebrospinal venous system may play a role in multiple sclerosis (MS) and that chronic cerebrospinal venous insufficiency...

Switching therapy and long-term adherence

#MSBlog: Long-term adherence to DMTs does occur. Can we assume these drugs are effective? Carvalho AT, Sá MJ. Switching and escalating therapy in long-lasting multiple sclerosis: not always necessary. ISRN Neurol. 2012;2012:451457. doi: 10.5402/2012/451457. Background: Although therapy switch is common among MSers, sometimes the initial prescribed treatment is maintained for a long period with...

Defining Fatigue

Kluger BM, Krupp LB, Enoka RM.Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy. Neurology. 2013;80(4):409-16. Fatigue is commonly reported in many neurologic illnesses, including multiple sclerosis, Parkinson disease, myasthenia gravis, traumatic brain injury, and stroke. Fatigue contributes substantially to decrements in quality of life and disability in these...

Research: Diagnosing NMO

Epub: Kim SM, et al. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler. 2013 Jan. AIM: Our aim was to evaluate the utility of aquaporin-4 antibodies (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD). METHODS: The clinical and radiological characteristics of 78 patients with NMOSD and 22 with multiple...

UCLP Bosses speak out against the actions of Genzyme

Thompson AJ, Giovannoni G. Removal of access to alemtuzumab for patients with aggressive multiple sclerosis. BMJ. 2013 Jan 18;346:f275. doi: 10.1136/bmj.f275. Team G speak out.  Although some treatments are now available for multiple sclerosis, better treatments are needed for people with aggressive disease. The need to find agents that can prevent or slow disease progression...

Vitamin D mop in the spinal fluid and Progression

Vitamin D-binding Protein in Cerebrospinal Fluid is Associated with Multiple Sclerosis Progression. Yang M, Qin Z, Zhu Y, Li Y, Qin Y, Jing Y, Liu S.Mol Neurobiol. 2013 Jan 22. [Epub ahead of print] Multiple sclerosis is a neurological disorder that presents with symptoms including inflammation, neurodegeneration, and demyelination of the central nervous system (CNS). Secondary progressive...

Imaging Myelin

Frullano L, Zhu J, Miller RH, Wang Y. Synthesis and characterization of a novel Gd-based contrast agent for magnetic resonance imaging of myelination, J Med Chem. 2013 Jan [Epub ahead of print] Myelin is a membrane system that fosters nervous impulse conduction in the vertebrate nervous system. Myelin sheath disruption is a common characteristic of several neurodegenerative diseases such as...

EUReMS: the European MS register

#MSBlog: EUReMS a new and powerful lobby for MSers in Europe! Pugliatti et al. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. Acta Neurol Scand Suppl. 2012;(195):24-30. doi: 10.1111/ane.12024. OBJECTIVES: MSers experience health-related quality of life (HRQoL) problems that differs across Europe, and the European Union...

Guest post: FUMADERM and PML – can we make conclusions for BG12?

#MSBlog: What does Prof. Gold, the PI on the BG12 programme, have to say about Fumaderm and PML? “In response to the intense interest on the blog concerning Fumaderm and PML and its possible implications for BG12, we invited Professor Doctor Ralf Gold to contribute a guest post on this topic! I hope it answers some of your questions. It has mine!” PROF. DR. RALF GOLD Recently two...

Translate

Categories

Recent Posts

Recent Comments

Archives